Umanbig

Umanbig is a Human Hepatitis B Immunoglobulin used for post-exposure prophylaxis against hepatitis B virus. It provides passive immunity by delivering antibodies to prevent infection. This product is administered via intramuscular injection and is sourced from EU-based manufacturing. Ideal for individuals exposed to HBV or at high risk of infection.

Human Hepatitis B Immunoglobulin is used to prevent hepatitis B infection after potential exposure, such as needlestick injuries or mucous membrane contact with infected blood. It is also administered to newborns born to mothers with active hepatitis B to reduce transmission risk. This immunoglobulin provides immediate, short-term protection by supplying pre-formed antibodies. It does not replace vaccination but works alongside it for immediate defense.

After administration, Umanbig provides passive immunity by delivering antibodies that neutralize the hepatitis B virus in the body. Users may experience temporary relief from anxiety related to potential infection following exposure. The effects typically begin within hours and can last for several weeks. Some individuals may notice mild soreness at the injection site.

Store Umanbig refrigerated between 2°C and 8°C (36°F and 46°F) and protect it from freezing. Do not use if the solution is cloudy or contains particles. Inform your healthcare provider of any known allergies, especially to human blood products. Keep the product in its original packaging until ready for use to maintain sterility.

No specific drug interactions are widely documented for Human Hepatitis B Immunoglobulin. However, live vaccines may have reduced effectiveness if administered shortly after immunoglobulin therapy. It is generally recommended to wait at least 3 months after receiving immunoglobulin before receiving live vaccines. Always consult a healthcare professional before combining therapies.